The UK’s Medicine and Healthcare products Regulatory Agency has already approved the booster dose of AstraZenenca’s Covid-19 vaccine, which is administered in India
The company has also started working with a large pharma company on the API supply of a recently launched animal and human health product
Oravax's vaccine technology is highly scalable for manufacturing and is easily transferable for wide scale logistical distribution, as there is no need for freezer storage
Soft-mist inhalation (SMI) technology allows for delivery of inhalation drugs from a small, portable hand-held inhaler device without the use of propellants
Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron
The three doses of ZyCoV-D are to be administered 28 days apart. The vaccine was given emergency use authorisation (EUA) by the Indian drug regulator on August 20
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
ALASTIN’s patented, differentiated technology and products are highly synergistic with Galderma’s premium portfolio
Booster dose is available to all residents aged 18+ and can be applied six months after the second dose of any other vaccine administered in UAE
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
Subscribe To Our Newsletter & Stay Updated
